Biosynex specializes in the research, development and manufacturing of fast diagnosis tests on membrane support for health professionals (biologists, clinicians, nurses and midwives). Products are used in the tropical diseases, autoimmune diseases, emergency markers and Infectious diseases fields. The company's activity is organized around 5 areas: - manufacturing of diagnosis tests for own account; - sale of diagnosis tests supplied by other manufacturers of semi-finished products; - research and development services for third party; - sale of licenses; - sale of biological reagents.

Employees

397

Sector

Medical Equipment, Supplies & Distribution

More about the company

Quotes

Date	Price	Change	Volume
20/07/26	€0.9100	+2.02%	23,008
17/07/26	€0.8920	-0.89%	1,050
16/07/26	€0.9000	-0.22%	2,162
15/07/26	€0.9020	-0.66%	5,825
14/07/26	€0.9080	+0.89%	1,144

Real-time Euronext Paris

More quotes

Income Statement and Estimates

More financial data

Market Closed - Euronext Paris Other stock markets 18:55:00 20/07/2026 +03			5-day change	1st Jan Change
0.9100 ^EUR	+2.02%		+2.71%	+52.68%

06-11	Triple update for Biosynex
06-11	An undisclosed buyer acquired Entire internal molecular biology business from Biosynex SA for ?4 million.	CI

Market Cap	16.77M 19.14M 15.51M 14.26M 26.94M 1.85B 27.36M 185M 72.65M 903M 71.88M 70.29M 3.11B	P/E 2024	-0.43x	P/E 2025	-0.19x
Enterprise Value	69.96M 79.85M 64.7M 59.46M 112M 7.7B 114M 773M 303M 3.77B 300M 293M 12.97B	EV / Sales 2024	0.71x	EV / Sales 2025	0.68x
Free-Float	40.35%	Yield 2024 *	-	Yield 2025	-

06-11	Triple update for Biosynex
06-11	An undisclosed buyer acquired Entire internal molecular biology business from Biosynex SA for ?4 million.	CI
05-25	Paris climbs on hopes of Middle East de-escalation
05-25	Biosynex announces the divestment of its molecular biology business
05-25	An undisclosed buyer signed a binding offer to acquire Entire internal molecular biology business from Biosynex SA for ?4 million.	CI
05-08	Biosynex SA Reports Earnings Results for the Full Year Ended December 31, 2025	CI
05-07	Biosynex SA Auditor Raises 'Going Concern' Doubt	CI
04-21	Thales, Vivendi, Mercialys, GTT... stocks to watch today in Paris
04-21	Biosynex postpones publication of annual accounts
03-24	Abivax, Ekinops, Sanofi... stocks to watch today in Paris
03-24	Observation period extended for Biosynex
02-06	A Biosynex Subsidiary to Receive $1.8 Million Grant
02-06	Aperam, Société Générale, Stellantis: Key Stocks to Watch Today in Paris

23/10/24	BIOSYNEX SA: CHEMBIO DIAGNOSTICS INC., A SUBSIDIARY OF BIOSYNEX, RECEIVES A GRANT FOR DEVELOPMENT OF A DPP CONGENITAL SYPHILIS ASSAY	EQ
27/04/23	Biosynex Completes Acquisition of Chembio Diagnostics, Inc.	AQ
13/04/23	Biosynex Extends Tender Offer for the shares of Chembio Diagnostics, Inc.	AQ
15/03/23	Biosynex Extends Tender Offer for the shares of Chembio Diagnostics, Inc.	AQ
01/02/23	Biosynex and Chembio Diagnostics Announce Definitive Acquisition Agreement	AQ

Biosynex Stock

Stocks

ALBIO

FR0011005933

Medical Equipment, Supplies & Distribution

Valuation: Biosynex

Chart: Biosynex

Latest news : Biosynex

Press Releases: Biosynex

News in other languages: Biosynex

Quotes and Performance

Course Extremes

Managers and Directors: Biosynex

Latest insider transactions

Diagnostic & Testing Substances

Financials

Company Profile

Quotes

Income Statement and Estimates

06-13	Agenda des dividendes et des AG France : GTT, Alten et Exail sur les tablettes
06-11	Bourse : J-1 avant SpaceX, Oracle à la peine, contrat pour Airbus
06-11	Une bonne grosse purge avant SpaceX
06-11	Triple actualité pour Biosynex
06-11	BIOSYNEX SA: BIOSYNEX ANNONCE LA REALISATION DEFINITIVE DE LA CESSION DE SON ACTIVITE DE BIOLOGIE MOLECULAIRE

1 day	+2.02%
1 week	+2.71%
Current month	+0.89%
1 month	+2.71%
3 months	+5.81%
6 months	+25.34%
Current year	+52.68%

1 week	0.89	0.96
1 month	0.8	1.07
Current year	0.56	1.57
1 year	0.46	1.57
3 years	0.46	11
5 years	0.46	28.78
10 years	0.46	30.38

Manager	Title	Age	Since
Larry Abensur CEO	Chief Executive Officer	71	24/06/2015
Thierry Paper CTO	Chief Tech/Sci/R&D Officer	63	01/01/2015
Oren Bitton PRN	Corporate Officer/Principal	-	-

Director	Title	Age	Since
Thierry Paper BRD	Director/Board Member	63	24/06/2015
Thomas Lamy BRD	Director/Board Member	-	24/06/2015
Larry Abensur CHM	Chairman	71	24/06/2015

Date	Insider	Type	Main position	Quantity	% Market Cap.
2/15/23 A	Elie Fraenckel	Buy	Director	2,500	0.0244%
2/15/23 A	Elie Fraenckel	Buy	Director	2,500	0.0244%
2/28/22 A	Larry Abensur	Buy	Chief Executive Officer	254	0.0023%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
BIOSYNEX	+2.02%	+2.71%	-28.63%	-90.84%	18.81M
GUARDANT HEALTH, INC.	-5.00%	-7.49%	+218.70%	+290.38%	20.67B
BIOMÉRIEUX	-1.10%	+3.44%	-39.02%	-23.29%	9.85B
LANTHEUS HOLDINGS, INC.	-2.96%	-1.17%	+48.76%	+17.03%	7B
10X GENOMICS, INC.	-1.19%	+1.15%	+255.72%	-28.12%	5.55B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	+3.43%	+7.18%	-14.36%	-20.83%	5.23B
ANDON HEALTH CO., LTD.	-8.46%	+23.30%	+84.85%	+105.62%	4.9B
CARIS LIFE SCIENCES, INC.	-5.64%	-8.42%	-48.46%	-	4.66B
DIASORIN S.P.A.	0.00%	+2.01%	-22.43%	-25.26%	4.2B
AUTOBIO DIAGNOSTICS CO., LTD.	+1.21%	+5.98%	-14.81%	-39.11%	2.72B
Average	-1.64%	+3.33%	+44.03%	+20.62%	6.48B
Weighted average by Cap.	-2.82%	+2.23%	+90.67%	+98.57%

	2024	2025
Net sales	101M 115M 93.55M 85.98M 163M 11.14B 165M 1.12B 438M 5.45B 434M 424M 18.76B	95.19M 109M 88.03M 80.9M 153M 10.48B 155M 1.05B 412M 5.13B 408M 399M 17.65B
Net income	-43.33M -49.45M -40.07M -36.83M -69.61M -4.77B -70.67M -479M -188M -2.33B -186M -182M -8.04B	-58.22M -66.45M -53.84M -49.48M -93.53M -6.41B -94.96M -644M -252M -3.14B -250M -244M -10.8B
Net Debt	52.94M 60.41M 48.95M 44.99M 85.04M 5.83B 86.33M 585M 229M 2.85B 227M 222M 9.82B	53.19M 60.7M 49.19M 45.21M 85.45M 5.86B 86.75M 588M 230M 2.86B 228M 223M 9.86B